Organogenesis Holdings Inc. provided earnings guidance for the year ending December 31, 2023. For the period, the company expects Net revenue between $433 million and $446 million, representing a decrease of approximately 1% to 4% year-over-year, as compared to net revenue of $450.9 million for the year ended December 31, 2022. Net income between $4 million and $9 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.015 USD | -0.50% | +22.59% | -28.36% |
01:01pm | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
05-10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.36% | 402M | |
+25.98% | 44.96B | |
+1.45% | 42.65B | |
+45.89% | 41.85B | |
-4.27% | 29.04B | |
+11.10% | 26.08B | |
-20.53% | 19.03B | |
+5.88% | 12.75B | |
+28.14% | 12.06B | |
-3.59% | 11.75B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023